Literature DB >> 14983979

Pregabalin (Pfizer).

Richard Huckle1.   

Abstract

Pregabalin is a gamma-aminobutyric acid analog that is under development by Pfizer for the potential treatment of central nervous system disorders, including epilepsy, neuropathic pain, fibromyalgia and generalized anxiety disorder. By April 2003, Pfizer had filed for approval of pregabalin in Europe for neuropathic pain and as an adjunctive therapy for epilepsy, and in October 2003 an NDA was filed for these indications and generalized anxiety disorder. At this time, phase III trials in fibromyalgia were ongoing.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14983979

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  9 in total

Review 1.  Pregabalin: in the treatment of postherpetic neuralgia.

Authors:  James E Frampton; Rachel H Foster
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical PK-PD study design.

Authors:  Gregor Bender; James Gosset; Jeff Florian; Keith Tan; Mark Field; Scott Marshall; Joost DeJongh; Robert Bies; Meindert Danhof
Journal:  Pharm Res       Date:  2009-08-11       Impact factor: 4.200

Review 3.  Pregabalin: in the treatment of painful diabetic peripheral neuropathy.

Authors:  James E Frampton; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  alpha(2)delta Modulators for Management of Compression Neuropathic Pain: A Review of Three Case Series.

Authors:  Tariq A Tramboo; Showket Gurkhoo
Journal:  Indian J Palliat Care       Date:  2009-07

Review 5.  Pregabalin: in the treatment of postherpetic neuralgia.

Authors:  Kate McKeage; Susan J Keam
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

6.  Effects of pregabalin on visceral pain responses and colonic compliance in rats.

Authors:  A Ravnefjord; M Brusberg; H Larsson; E Lindström; V Martínez
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

7.  In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders.

Authors:  Andrew Alt; Brianne Weiss; Ann Marie Ogden; Xia Li; Scott D Gleason; David O Calligaro; David Bleakman; Jeffrey M Witkin
Journal:  Psychopharmacology (Berl)       Date:  2006-02-10       Impact factor: 4.530

8.  Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome.

Authors:  L A Houghton; C Fell; P J Whorwell; I Jones; D P Sudworth; J D Gale
Journal:  Gut       Date:  2007-04-19       Impact factor: 23.059

9.  Alpha 2 Delta (α(2)δ) Ligands, Gabapentin and Pregabalin: What is the Evidence for Potential Use of These Ligands in Irritable Bowel Syndrome.

Authors:  Jeremy D Gale; Lesley A Houghton
Journal:  Front Pharmacol       Date:  2011-06-09       Impact factor: 5.810
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.